Cat. No. | Product name | CAS No. |
DCC5409 |
Vezf1-in-t4
Novel Inhibitor of the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1 |
|
DCC5410 |
Vhl-hif1α Inhibitor-tg0
The first sub-micromolar inhibitor of the VHL-HIF1α interaction |
|
DCC5411 |
Vibsanin A
Natural protein kinase C (PKC) activator and HSP90 inhibitor, sensitizing human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn |
72506-14-0 |
DCC5412 |
Vicagrel
Clopidogrel analog as an antiplatelet agent |
1314081-53-2 |
DCC5413 |
Vidarabine Monohydrate
Broad spectrum antibiotic, inhibiting adenylyl cyclase type 5 (AC5) and protecting against chronic coronary artery occlusion (CAO) |
24356-66-9 |
DCC5414 |
Vilanterol
Selective long-acting beta2-adrenergic agonist (LABA) with inherent 24-hour activity for once daily treatment of COPD and asthma |
503068-34-6 |
DCC5415 |
Vincamine V2a
Novel antagonist against hypocretin (orexin) receptor 2, significantly preventing acute morphine-conditioned place preference (CPP) and stress-induced reinstatement of extinguished morphine-CPP in mouse models of opioid reward and relapse |
|
DCC5416 |
Vincapusine
Natural inhibitor of 3C-like protease (3CLpro), targeting SARS-CoV-2 3CLpro, SARS-CoV 3CLpro and MERS-CoV 3CLpro |
80248-97-1 |
DCC5417 |
Vincetoxicoside A
Natural antimicrobial, antioxidant, and anti-inflammator agent |
18016-58-5 |
DCC5418 |
Virodhamine Trifluoroacetate
Endogenous cannabinoid receptor mixed agonist/antagonist, being a full agonist at GPR55 and CB2 and partial agonist/antagonist at CB1 |
1415264-56-0 |
DCC5419 |
Vitexin 4"-o-glucoside
Natural inhibitor of ST2 (IL1RL1) |
178468-00-3 |
DCC5420 |
Viviren
Coelenterazine analog for bioluminescence imaging (BLI) |
|
DCC5421 |
Vmy-1-101
Fluorescent cyclin-dependent kinase inhibitor, blocking the proliferation of human breast cancer cells |
1209002-42-5 |
DCC5422 |
vmy-2-95
Novel and selective desensitizer of |
1434047-61-6 |
DCC5423 |
Setmelanotide Tfa Salt
Featured
Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals |
920014-72-8 |
DCC5424 |
Voa Analog 19
Novel potent VEGFR2 modulator, exhibiting increased antiangiogenic potency than voacangine against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects, resulting in significant tumor cell death in a mouse xenograft model |
|
DCC5425 |
Voclosporin
Novel calcineurin inhibitor and immunosuppressive agent |
515814-00-3 |
DCC5426 |
Vonoprazan Fumurate
Novel potassium-competitive acid blocker |
881681-01-2 |
DCC5427 |
Vpc-00628
Novel potent and highly selective type-II inhibitor of p38α/β, targeting an inactive state of the kinases induced by a unique folded P-loop conformation |
|
DCC5428 |
Vpc-13163
Potent Antiandrogen, Targeting the BF3 Site of the Androgen Receptor and Inhibiting Enzalutamide-Resistant Prostate Cancer |
6637-10-1 |
DCC5429 |
Vpc-16606
Novel potent and selective inhibitor of ERα-dependent cell growth and gene expression, preventing the interaction between ERα-LBD and SRC-3 fusion proteins in a dose-dependent manner |
2027540-49-2 |
DCC5430 |
Vpc24191
S1P1/S1P3 receptor agonist |
799268-83-0 |